Ameriprise Financial Inc. Has $39.90 Million Stock Holdings in The Clorox Company (NYSE:CLX)

Ameriprise Financial Inc. grew its position in The Clorox Company (NYSE:CLX) by 14.8% during the 4th quarter, HoldingsChannel reports. The firm owned 245,686 shares of the company’s stock after purchasing an additional 31,624 shares during the quarter. Ameriprise Financial Inc.’s holdings in Clorox were worth $39,902,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Brooklyn Investment Group raised its holdings in Clorox by 163.8% in the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company’s stock worth $25,000 after purchasing an additional 95 shares during the period. Redwood Park Advisors LLC acquired a new stake in Clorox in the fourth quarter worth $26,000. Millstone Evans Group LLC acquired a new stake in Clorox in the fourth quarter worth $31,000. Asset Planning Inc acquired a new stake in Clorox in the fourth quarter worth $32,000. Finally, GKV Capital Management Co. Inc. acquired a new stake in Clorox in the fourth quarter worth $32,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the business’s stock in a transaction on Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is currently owned by insiders.

Clorox Stock Down 2.2%

Shares of CLX stock opened at $134.79 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The Clorox Company has a 1 year low of $127.60 and a 1 year high of $171.37. The firm’s fifty day moving average price is $142.37 and its two-hundred day moving average price is $154.03. The firm has a market capitalization of $16.60 billion, a P/E ratio of 36.83, a PEG ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter in the previous year, the firm posted $1.71 earnings per share. The firm’s quarterly revenue was down 8.0% on a year-over-year basis. On average, equities analysts predict that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 9th. Stockholders of record on Wednesday, April 23rd were given a $1.22 dividend. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date of this dividend was Wednesday, April 23rd. Clorox’s dividend payout ratio (DPR) is presently 87.61%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CLX shares. Morgan Stanley cut their target price on shares of Clorox from $165.00 to $150.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Evercore ISI set a $140.00 price objective on shares of Clorox and gave the stock an “underperform” rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price objective on shares of Clorox from $151.00 to $144.00 and set a “neutral” rating on the stock in a report on Tuesday, May 6th. UBS Group dropped their price objective on shares of Clorox from $176.00 to $154.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. Finally, Citigroup dropped their price objective on shares of Clorox from $165.00 to $150.00 and set a “neutral” rating on the stock in a report on Monday, April 14th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $151.23.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.